{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:09:08Z","timestamp":1787162948918,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T00:00:00Z","timestamp":1720224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T00:00:00Z","timestamp":1720224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82170215, 82293634, 81970161, 81870144, 82200241 and 82270178"],"award-info":[{"award-number":["No. 82170215, 82293634, 81970161, 81870144, 82200241 and 82270178"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82170215, 82293634, 81970161, 81870144, 82200241 and 82270178"],"award-info":[{"award-number":["No. 82170215, 82293634, 81970161, 81870144, 82200241 and 82270178"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["No. 2021YFC2500300-2021YFC2500302 and 2022YFA1105000"],"award-info":[{"award-number":["No. 2021YFC2500300-2021YFC2500302 and 2022YFA1105000"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["No. 2023A1515010111"],"award-info":[{"award-number":["No. 2023A1515010111"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>T(8;21)(q22;q22.1)\/AML1-ETO positive acute myeloid leukemia (AE-AML) is sensitive to conventional chemotherapy with a favorable prognosis. However, recent small case reports suggest the limited effectiveness of venetoclax (VEN) and hypomethylating agents (HMA) in treating AE-AML. The aim of this retrospective study was to evaluate the effectiveness of VEN plus AZA (VA) in AE-AML and explore whether adding homoharringtonine (HHT) to VA (VAH) could improve the response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients who received VEN plus AZA and HHT (VAH) or VEN plus AZA (VA) regimens were included in this retrospective study. The endpoints of this study were to evaluate the rate of composite complete remission (CRc), measurable residual disease (MRD), event-free survival (EFS), overall survival (OS), and relapse between VAH and VA groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 32 AE-AML patients who underwent VA or VAH treatments (newly diagnosed with VA, ND-VA,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20098; relapsed\/refractory with VA, R\/R-VA,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200910; relapsed\/refractory with VAH, R\/R-VAH,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200914) were included. The CR (complete remission) \/CRi (CR with incomplete count recovery) rate of ND-VA, R\/R-VA and R\/R-VAH were 25%, 10%, and 64.3%, respectively. Measurable residual disease (MRD) negative was observed in 66.7% of R\/R-VAH and none of VA-R\/R patients. Co-occurring methylation mutations are associated with poor outcomes with VA but exhibit a more favorable response with VAH treatment. Additionally, patients with c-kit mutation presented inferior outcomes with both VEN-based regimens. All regimens were tolerated well by all patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our data confirmed the poor response of VA in AE-AML, whether used as frontline or salvage therapy. Adding HHT to VA may improve outcomes and enhance the efficacy of VEN in this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00432-024-05861-9","type":"journal-article","created":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T22:01:37Z","timestamp":1720216897000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Homoharringtonine may help improve the outcomes of venetoclax and azacitidine in AML1-ETO positive acute myeloid leukemia"],"prefix":"10.1007","volume":"150","author":[{"given":"Zhao","family":"Yin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zurong","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangyang","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongjun","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinquan","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziwen","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihua","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Xuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejie","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengcheng","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qifa","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baohong","family":"Ping","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guopan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,6]]},"reference":[{"issue":"2","key":"5861_CR1","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/s1470-2045(18)30010-x","volume":"19","author":"CD DiNardo","year":"2018","unstructured":"DiNardo CD, Pratz KW, Letai A et al (2018) Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol Feb 19(2):216\u2013228. https:\/\/doi.org\/10.1016\/s1470-2045(18)30010-x","journal-title":"Lancet Oncol Feb"},{"key":"5861_CR2","unstructured":"National Comprehensive Cancer Network guidelines Acute myeloid leukemia Version 1.2023, https:\/\/www.nccn.org"},{"issue":"10","key":"5861_CR3","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1158\/2159-8290.Cd-16-0313","volume":"6","author":"M Konopleva","year":"2016","unstructured":"Konopleva M, Pollyea DA, Potluri J et al (2016) Efficacy and Biological correlates of response in a phase II study of Venetoclax Monotherapy in patients with Acute Myelogenous Leukemia. Cancer Discov Oct 6(10):1106\u20131117. https:\/\/doi.org\/10.1158\/2159-8290.Cd-16-0313","journal-title":"Cancer Discov Oct"},{"issue":"11","key":"5861_CR4","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1182\/blood.2019003988","volume":"12","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Tiong IS, Quaglieri A et al (2020) Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood Mar 12(11):791\u2013803. https:\/\/doi.org\/10.1182\/blood.2019003988","journal-title":"Blood Mar"},{"issue":"8","key":"5861_CR5","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1038\/s43018-020-0103-x","volume":"1","author":"H Zhang","year":"2020","unstructured":"Zhang H, Nakauchi Y, K\u00f6hnke T et al (2020) Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia. Nat Cancer Aug 1(8):826\u2013839. https:\/\/doi.org\/10.1038\/s43018-020-0103-x","journal-title":"Nat Cancer Aug"},{"issue":"12","key":"5861_CR6","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"22","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR et al (2022) Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood Sep 22(12):1345\u20131377. https:\/\/doi.org\/10.1182\/blood.2022016867","journal-title":"Blood Sep"},{"issue":"2","key":"5861_CR7","doi-asserted-by":"publisher","first-page":"134","DOI":"10.3760\/cma.j.issn.0253-2727.2022.02.008","volume":"14","author":"WJ Yu","year":"2022","unstructured":"Yu WJ, Jia JS, Wang J et al (2022) Short-term efficacy of venetoclax combined with azacitidine in acute myeloid leukemia: a single-institution experience. Zhonghua Xue Ye Xue Za Zhi Feb 14(2):134\u2013140. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-2727.2022.02.008","journal-title":"Zhonghua Xue Ye Xue Za Zhi Feb"},{"issue":"1","key":"5861_CR8","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41408-023-00928-1","volume":"11","author":"K Zhang","year":"2023","unstructured":"Zhang K, Zhang X, Xu Y et al (2023) Efficacy of venetoclax combined with hypomethylating agents in young, and unfit patients with newly diagnosed core binding factor acute myeloid leukemia. Blood Cancer J Oct 11(1):155. https:\/\/doi.org\/10.1038\/s41408-023-00928-1","journal-title":"Blood Cancer J Oct"},{"key":"5861_CR9","doi-asserted-by":"publisher","unstructured":"Weng G, Zhang Y, Yu G et al (Mar 2023) Genetic characteristics predict response to venetoclax plus hypomethylating agents in relapsed or refractory acute myeloid leukemia. J Intern Med 293(3):329\u2013339. https:\/\/doi.org\/10.1111\/joim.13581","DOI":"10.1111\/joim.13581"},{"issue":"1","key":"5861_CR10","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13045-023-01437-1","volume":"29","author":"H Jin","year":"2023","unstructured":"Jin H, Zhang Y, Yu S et al (2023) Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed\/Refractory AML: a Multicenter, phase 2 trial. J Hematol Oncol Apr 29(1):42. https:\/\/doi.org\/10.1186\/s13045-023-01437-1","journal-title":"J Hematol Oncol Apr"},{"issue":"7","key":"5861_CR11","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/s1470-2045(13)70152-9","volume":"14","author":"J Jin","year":"2013","unstructured":"Jin J, Wang JX, Chen FF et al (2013) Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a multicentre, open-label, randomised, controlled phase 3 trial. Lancet Oncol Jun 14(7):599\u2013608. https:\/\/doi.org\/10.1016\/s1470-2045(13)70152-9","journal-title":"Lancet Oncol Jun"},{"key":"5861_CR12","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1756-8722-7-2","volume":"3","author":"S L\u00fc","year":"2014","unstructured":"L\u00fc S, Wang J (2014) Homoharringtonine and omacetaxine for myeloid hematological malignancies. J Hematol Oncol Jan 3:7:2. https:\/\/doi.org\/10.1186\/1756-8722-7-2","journal-title":"J Hematol Oncol Jan"},{"issue":"31","key":"5861_CR13","doi-asserted-by":"publisher","first-page":"4881","DOI":"10.1200\/jco.22.02836","volume":"1","author":"J Li","year":"2023","unstructured":"Li J, Gao J, Liu A et al (2023) Homoharringtonine-based induction regimen improved the Remission Rate and Survival Rate in Chinese Childhood AML: a Report from the CCLG-AML 2015 protocol study. J Clin Oncol Nov 1(31):4881\u20134892. https:\/\/doi.org\/10.1200\/jco.22.02836","journal-title":"J Clin Oncol Nov"},{"issue":"1","key":"5861_CR14","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.jmb.2009.04.005","volume":"29","author":"G G\u00fcrel","year":"2009","unstructured":"G\u00fcrel G, Blaha G, Moore PB, Steitz TA (2009) U2504 determines the species specificity of the A-site cleft antibiotics: the structures of tiamulin, homoharringtonine, and bruceantin bound to the ribosome. J Mol Biol May 29(1):146\u2013156. https:\/\/doi.org\/10.1016\/j.jmb.2009.04.005","journal-title":"J Mol Biol May"},{"key":"5861_CR15","doi-asserted-by":"publisher","first-page":"692497","DOI":"10.3389\/fonc.2021.692497","volume":"11","author":"Y Shi","year":"2021","unstructured":"Shi Y, Ye J, Yang Y et al (2021) The Basic Research of the combinatorial therapy of ABT-199 and homoharringtonine on Acute myeloid leukemia. Front Oncol 11:692497. https:\/\/doi.org\/10.3389\/fonc.2021.692497","journal-title":"Front Oncol"},{"issue":"6","key":"5861_CR16","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1182\/blood.2021013156","volume":"10","author":"CP Mill","year":"2022","unstructured":"Mill CP, Fiskus W, DiNardo CD et al (2022) Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2. Blood Feb 10(6):907\u2013921. https:\/\/doi.org\/10.1182\/blood.2021013156","journal-title":"Blood Feb"},{"issue":"Supplement 1","key":"5861_CR17","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1182\/blood-2020-138676","volume":"136","author":"G Yu","year":"2020","unstructured":"Yu G, Xu N, Huang F et al (2020) Combination of Homoharringtonine with Venetoclax and Azacitidine Excerts Better Treatment Response in Relapsed \/Refractory Acute myeloid leukemia. Blood 136(Supplement 1):26\u201327. https:\/\/doi.org\/10.1182\/blood-2020-138676","journal-title":"Blood"},{"issue":"7","key":"5861_CR18","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O et al (2022) The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and Histiocytic\/Dendritic neoplasms. Leuk Jul 36(7):1703\u20131719. https:\/\/doi.org\/10.1038\/s41375-022-01613-1","journal-title":"Leuk Jul"},{"issue":"9","key":"5861_CR19","doi-asserted-by":"publisher","first-page":"705","DOI":"10.3760\/cma.j.issn.0253-2727.2023.09.001","volume":"14","author":"Leukemia & Lymphoma Group CSoH, Chinese Medical Association","year":"2023","unstructured":"Leukemia & Lymphoma Group CSoH, Chinese Medical Association (2023) Chinese guidelines for diagnosis and treatment of adult acute myeloid leukemia (not APL) (2023). Zhonghua Xue Ye Xue Za Zhi. Sep 14(9):705\u2013712. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-2727.2023.09.001","journal-title":"Sep"},{"issue":"5","key":"5861_CR20","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1038\/s41375-019-0686-3","volume":"34","author":"S Yu","year":"2020","unstructured":"Yu S, Huang F, Wang Y et al (2020) Haploidentical transplantation might have superior graft-versus-leukemia effect than HLA-matched sibling transplantation for high-risk acute myeloid leukemia in first complete remission: a prospective multicentre cohort study. Leuk May 34(5):1433\u20131443. https:\/\/doi.org\/10.1038\/s41375-019-0686-3","journal-title":"Leuk May"},{"issue":"33","key":"5861_CR21","doi-asserted-by":"publisher","first-page":"3848","DOI":"10.1200\/jco.21.02823","volume":"20","author":"TM Kadia","year":"2022","unstructured":"Kadia TM, Reville PK, Wang X et al (2022) Phase II study of Venetoclax added to Cladribine Plus Low-Dose Cytarabine Alternating with 5-Azacitidine in older patients with newly diagnosed Acute myeloid leukemia. J Clin Oncol Nov 20(33):3848\u20133857. https:\/\/doi.org\/10.1200\/jco.21.02823","journal-title":"J Clin Oncol Nov"},{"issue":"11","key":"5861_CR22","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1038\/s41409-021-01416-5","volume":"56","author":"A Zucenka","year":"2021","unstructured":"Zucenka A, Vaitekenaite V, Maneikis K et al (2021) Venetoclax-based salvage therapy followed by Venetoclax and DLI maintenance vs. FLAG-Ida for relapsed or refractory acute myeloid leukemia after allogeneic stem cell transplantation. Bone Marrow Transpl Nov 56(11):2804\u20132812. https:\/\/doi.org\/10.1038\/s41409-021-01416-5","journal-title":"Bone Marrow Transpl Nov"},{"issue":"2","key":"5861_CR23","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s11523-024-01039-y","volume":"19","author":"D Jin","year":"2024","unstructured":"Jin D, Chen H, He J et al (2024) Impact of AML1\/ETO Fusion on the efficacy of Venetoclax Plus Hypomethylating agents in newly diagnosed Acute myeloid leukemia. Target Oncol Mar 19(2):237\u2013249. https:\/\/doi.org\/10.1007\/s11523-024-01039-y","journal-title":"Target Oncol Mar"},{"issue":"1","key":"5861_CR24","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/s41408-023-00948-x","volume":"27","author":"M Wang","year":"2023","unstructured":"Wang M, Cao HY, Tan KW et al (2023) Venetoclax plus hypomethylating agents in newly diagnosed acute myeloid leukemia patients with RUNX1::RUNX1T1: a retrospective propensity score matching study. Blood Cancer J Nov 27(1):173. https:\/\/doi.org\/10.1038\/s41408-023-00948-x","journal-title":"Blood Cancer J Nov"},{"issue":"6","key":"5861_CR25","doi-asserted-by":"publisher","first-page":"501","DOI":"10.3760\/cma.j.issn.0253-2727.2023.06.011","volume":"14","author":"RH Mi","year":"2023","unstructured":"Mi RH, Chen L, Wang L, Ai H, Yin QS, Wei XD (2023) Retrospective analysis of the efficacy and safety of Venetoclax-based regimen in the treatment of 12 cases of acute myeloid leukemia with t (8; 21). Zhonghua Xue Ye Xue Za Zhi Jun 14(6):501\u2013504. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-2727.2023.06.011","journal-title":"Zhonghua Xue Ye Xue Za Zhi Jun"},{"issue":"9","key":"5861_CR26","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41408-021-00541-0","volume":"21","author":"NE Rahmani","year":"2021","unstructured":"Rahmani NE, Ramachandra N, Sahu S et al (2021) ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine. Blood Cancer J Sep 21(9):157. https:\/\/doi.org\/10.1038\/s41408-021-00541-0","journal-title":"Blood Cancer J Sep"},{"issue":"16","key":"5861_CR27","doi-asserted-by":"publisher","first-page":"4328","DOI":"10.1182\/blood-2009-09-242545","volume":"21","author":"B Steffen","year":"2011","unstructured":"Steffen B, Knop M, Bergholz U et al (2011) AML1\/ETO induces self-renewal in hematopoietic progenitor cells via the Groucho-related amino-terminal AES protein. Blood Apr 21(16):4328\u20134337. https:\/\/doi.org\/10.1182\/blood-2009-09-242545","journal-title":"Blood Apr"},{"issue":"7","key":"5861_CR28","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.1128\/mcb.24.7.2890-2904.2004","volume":"24","author":"C M\u00fcller-Tidow","year":"2004","unstructured":"M\u00fcller-Tidow C, Steffen B, Cauvet T et al (2004) Translocation products in acute myeloid leukemia activate the wnt signaling pathway in hematopoietic cells. Mol Cell Biol Apr 24(7):2890\u20132904. https:\/\/doi.org\/10.1128\/mcb.24.7.2890-2904.2004","journal-title":"Mol Cell Biol Apr"},{"issue":"48","key":"5861_CR29","doi-asserted-by":"publisher","first-page":"eadh1436","DOI":"10.1126\/sciadv.adh1436","volume":"9","author":"Y Nishida","year":"2023","unstructured":"Nishida Y, Ishizawa J, Ayoub E et al (2023) Enhanced TP53 reactivation disrupts MYC transcriptional program and overcomes venetoclax resistance in acute myeloid leukemias. Sci Adv Dec 9(48):eadh1436. https:\/\/doi.org\/10.1126\/sciadv.adh1436","journal-title":"Sci Adv Dec"},{"issue":"5","key":"5861_CR30","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1158\/1078-0432.Ccr-15-1191","volume":"1","author":"M Klanova","year":"2016","unstructured":"Klanova M, Andera L, Brazina J et al (2016) Targeting of BCL2 family proteins with ABT-199 and Homoharringtonine reveals BCL2- and MCL1-Dependent subgroups of diffuse large B-Cell lymphoma. Clin Cancer Res Mar 1(5):1138\u20131149. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-15-1191","journal-title":"Clin Cancer Res Mar"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-024-05861-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-024-05861-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-024-05861-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T13:07:47Z","timestamp":1723036067000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-024-05861-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,6]]},"references-count":30,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["5861"],"URL":"https:\/\/doi.org\/10.1007\/s00432-024-05861-9","relation":{},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,6]]},"assertion":[{"value":"27 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in compliance with Declaration of Helsinki principles. All procedures were approved by the ethics committee review board of each participating hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from the the patients in our study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"336"}}